Organization (Industry)
ONCOMED
ClinicalTrials.gov lists ONCOMED as lead sponsor of 28 trials. It has 3 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ONCOMED: 28 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Neoplasm Metastasis | 9 |
| Pancreatic Neoplasms | 5 |
| Colorectal Neoplasms | 4 |
| Lung Neoplasms | 3 |
| Fallopian Tube Neoplasms | 2 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2017 | 3 |
| 2016 | 3 |
| 2015 | 3 |
| 2014 | 3 |
| 2013 | 6 |
| 2012 | 4 |
| 2011 | 1 |
| 2010 | 4 |
| 2008 | 1 |
Recruitment duration, a model prediction: none of the 28 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| GEMCITABINE | Pancreatic Neoplasms | Phase 2 | 4 |
| NAB paclitaxel | Pancreatic Neoplasms | Phase 2 | 4 |
| OMP-59R5 | Pancreatic Neoplasms | Phase 1/2 | 1 |
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| GEMCITABINE | 4 |
| NAB paclitaxel | 4 |
| CARBOPLATIN | 1 |
| PEMETREXED | 1 |
| ETOPOSIDE | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 80% on time (n=5) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
| Breast cancer research and treatment | 1 |
| Cancer medicine | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Investigational new drugs | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 94 | 0 | 2021-06-29 |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Novotech (Australia) Pty Limited | Uses vendor | 3 |
| Novotech (Australia) Pty Limited | Co sponsors trial with | 2 |
| Bristol Myers Squibb Co | Co sponsors trial with | 1 |
Latest dated events (122)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2021-06-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2020-12-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2020-08-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2020-01-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2019-03-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 122 events.
Biomarker capability evidence (75)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CD274 | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| EPO | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 75 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.